Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations inERBB2andERBB3
Author:
Affiliation:
1. Foundation Medicine Inc; Cambridge Massachusetts
2. Department of Pathology; Albany Medical Center; Albany New York
3. Department of Medical Oncology and Therapeutics Research City of Hope; Duarte California
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference90 articles.
1. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen;Schechter;Nature,1984
2. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis;Moasser;Oncogene,2007
3. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin;Chmielecki;Oncologist,2015
4. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009
5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010
Cited by 165 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Development and biological evaluation of 68Ga-labeled peptides for potential application in HER2-positive colorectal cancer;Bioorganic Chemistry;2024-10
2. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10
3. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial;The Lancet Oncology;2024-09
4. Biological and molecular targets for targeted therapy in colorectal cancer (literature review);Practical oncology;2024-08-02
5. ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high (MSI‐H) molecular subtype;Molecular Oncology;2024-07-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3